gutflix
GI learning, personalised

Summary

LONG-TERM EXPERIENCE WITH USTEKINUMAB IN ULCERATIVE COLITIS PATIENTS: A REAL LIFE MULTICENTRE SPANISH COHORT

María Dolores Martín-Arranz

UEG Week Copenhagen 2023 | Poster

IBD

October 15, 2023

A multicentre observational study reports real-world effectiveness, safety, and persistence of ustekinumab in highly refractory ulcerative colitis patients over 24 months of follow-up.

KEY POINTS

- Clinical remission rates (Partial Mayo Score ≤2) were 39.6% at 8 weeks, 41% at 24 weeks, 51% at 52 weeks, 61% at 18 months, and 57.7% at 24 months.
- Faecal calprotectin normalized in 39.6%, 41%, 51%, 61%, and 58% of patients at 8, 24, and 52 weeks and at 18 and 24 months respectively.
- During follow-up, 54% of patients required dose interval reduction after a median of 22.3 weeks, and 18.5% received IV reinduction doses after 27.7 weeks.
- Fewer previous anti-TNF agents was associated with clinical response, and loss of response to anti-TNF was associated with faecal calprotectin normalization.
- Adverse events occurred in 4.6% of patients, with drug persistence rates of 98%, 91%, 83%, and 81% at 8, 24, 48, and 96 weeks respectively.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/d4fbe356-743b-11ee-b37d-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.